Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

December 12, 2028

Study Completion Date

December 12, 2029

Conditions

DiabetesType 2 Diabetes

Interventions

BIOLOGICAL

mesenchymal stem cells with OCN-19

The patient received mesenchymal stem cells with OCN-19 three times

BIOLOGICAL

Mesenchymal stem cells

Ordinary mesenchymal stem cells were given

BIOLOGICAL

albumin injection

Placebo

Trial Locations (1)

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors

lead

Lu jin ，MD

OTHER